Rapid WGS Shortens Time to Genomic Reports in Children With Cancer

Overview

In a single-center study of 54 children with suspected or confirmed cancer, rapid whole-genome sequencing (rWGS) reduced the mean time to a clinically interpretable genomic report from 42 days with routine testing to 3 days. rWGS detected 147 of 155 clinically actionable germline and tumor variants identified by any method. Clinicians reported measurable care improvements in 17 of 35 prospectively assessed patients.

Background

Molecular characterization can inform diagnosis, risk stratification, and treatment planning in pediatric cancer. The study evaluated whether a rapid whole-genome sequencing workflow could provide clinically interpretable results sooner than routine whole-genome sequencing and conventional molecular tests.

Data Highlights

Key Findings

• The study included children with hematologic malignancies and solid tumors, including leukemia, lymphoma, central nervous system tumors, neuroblastoma, and Wilms tumor.
• rWGS detected 147 of 155 clinically actionable germline and tumor variants identified by any method, compared with 138 of 155 for routine WGS.
• The eight variants not detected by rWGS did not change diagnosis or management in the affected patients, according to the study.
• Mean routine WGS turnaround was 63 days for hematologic malignancies and 29 days for solid tumors; rWGS turnaround was 3 days for both groups.
• Clinicians reported measurable care improvements in 17 of 35 prospectively assessed patients, including faster diagnosis or risk stratification, access to precision treatments, and avoidance of unnecessary investigations or therapies.
• Examples included identification of a BRAF fusion in a child with pancreatic cancer that enabled targeted treatment, and diagnosis of non-malignant conditions in two children with soft tissue lesions, avoiding potentially harmful biopsy and treatment.

Clinical Implications

The study reports that rWGS provided results within a timeframe relevant to initial treatment decisions and supplied information including leukemia classification, measurable residual disease markers, risk information, and pharmacogenomic data. The researchers caution that the small, single-center, non-randomized study was not designed to establish clinical impact or cost savings. They state that larger multicenter studies are needed to assess reproducibility, cost-effectiveness, and scalability.

Conclusion

In this cohort, rWGS shortened the mean time to a clinically interpretable genomic report and identified most clinically actionable variants found across testing methods. The study authors state that larger multicenter studies are needed to assess reproducibility, cost-effectiveness, and scalability before wider implementation.

Related Resources & Content

1. Nature Communications, 2026 — Rapid Whole Genome Sequencing Enhances Pediatric Cancer Diagnosis
2. NCCN Clinical Practice Guidelines in Oncology, 2025 — Pediatric Acute Lymphoblastic Leukemia
3. the pathologist, 2017 — The Need for (Sequencing) Speed
4. JAMA Network Open — Utilizing Whole Genome Sequencing for Diagnosis and Healthcare Management in Severely Ill Pediatric Patients
5. the pathologist, 2023 — A Rare Resolve
6. the pathologist — Ode to WGS
7. Rapid Whole Genome Sequencing Enhances Pediatric Cancer Diagnosis | Nature Communications
8. NCCN Clinical Practice Guidelines in Oncology: Pediatric Acute Lymphoblastic Leukemia